AETIONOMY clinical study recruitment reaches milestone of 200 patients recruited
AETIONOMY an IMI funded project, has now recruited over 200 people into the Parkinson’s Disease portion of the European clinical study on neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. This milestone means that the project is 50% completed in both the AD and the PD portion. The Alzheimer’s disease portion is being recruited via EPAD* which has now recruited a total of 123 subjects of which 58 were recruited at the joint center BBRC.
Within the project, patients with neurodegenerative diseases and healthy people are providing blood and cerebrospinal samples to undergo detailed molecular analysis at leading European laboratories. The purpose of AETIONOMY is to propose novel patient classification based on mechanism-based taxonomies, for both PD and AD. ‘The AETIONOMY study will allow us to validate in real patients two hypotheses for PD and for AD,’ explains the study coordinator Prof. Jean Christophe Corvol of ICM, Paris. ‘This will then allow clinicians to stratify patients according to biological mechanisms of the disease and potentially to target specific sub-population for drug development.’